Table 4. Effects on Cell Growth (IC50, μM) of Human Glioma (U87), Colon (LoVo, HCT), and Breast (MDA-MB-231, MCF7, SkBr3) Cancer Cells by Compounds 1, 2a, and 2c and Liquiritigenina.
| IC50 (μM) |
||||||
|---|---|---|---|---|---|---|
| compd | U87 | LoVo | HCT | MDA231 | MCF7 | SkBr3 |
| liquiritigenin | 88.3 ± 7.8 | 77.7 ± 2.9 | 51.4 ± 2.9 | 167 ± 9 | >250 | 175.6 ± 8.9 |
| 1 | 45.8 ± 4.2 | 36.7 ± 2.7 | 27.4 ± 4.1 | 12.4 ± 1.4 | 16.4 ± 2.6 | 96.2 ± 3.3 |
| 2a | 35.0 ± 1.7 | 38.1 ± 1.6 | 17.2 ± 2.9 | 9.3 ± 1.2 | 8.7 ± 1.4 | 86.3 ± 5.6 |
| 2c | 68.8 ± 6.5 | 27.1 ± 2.8 | 15.2 ± 2.0 | 10.0 ± 3.1 | 2.7 ± 0.7 | 92.4 ± 4.8 |
a
IC50: inhibitory concentration causing a 50% reduction in cell growth, in μM. Mean values ± SD calculated from at least two triplicate cytotoxicity experiments (see Experimental Section).